
An Italian study examined memory concerns, health factors and p-Tau217 results. Its findings support a broader discussion with a clinician.

On September 29, 2026, researchers published a study in Neurological Sciences on people assessed at the Monza Brain Health Service in Italy. The study examined potentially modifiable health factors and a blood biomarker among people reporting cognitive changes.
The researchers analysed 186 consecutive attendees at the service. Of these, 132 were classified as having subjective cognitive decline, or SCD. The study was a real-world, cross-sectional analysis.
SCD describes a person's sense that their thinking or memory has declined while performance on standard neuropsychological tests remains normal. The term describes reported cognitive change rather than a finding from a blood test.
In the SCD group, the authors reported these potentially modifiable factors:
Sleep impairment was a broad category in this study. It included self-reported sleep issues, suspected or confirmed REM sleep behaviour disorder, or obstructive sleep apnoea. The 70% figure therefore does not refer to a single sleep condition.
That distinction matters when reading the findings. Different sleep concerns were brought into the same category, so the percentage alone does not explain what kind of sleep problem an individual had.
Plasma p-Tau217 results were available for 84 participants with SCD. Among them, 27 (32%) had levels above the study's 0.15 pg/mL threshold.
The authors explicitly cautioned that this threshold did not establish confirmed amyloid status and was not a diagnosis of Alzheimer's disease. It was used to separate participants into groups for the analysis.
Participants above the threshold were older. The researchers also found differences in some cognitive-test results and other blood-biomarker and MRI measures. Some imaging differences remained significant after age adjustment, while other comparisons did not.
The service's disclosure protocol brought together p-Tau217 results, APOE genotype and an individualized dementia-risk profile. Tailored risk-reduction recommendations followed. Psychological questionnaires were completed one week after disclosure.
Disclosure findings were available for 42 participants with SCD. The authors reported that almost all found the discussion useful and informative. Only one expressed a need for psychological support. Approximately two thirds said they felt more motivated to change their lifestyle.
The emotional picture was mixed. Participants above the p-Tau217 threshold had higher event-related distress scores. The difference was marginal after correction for multiple comparisons, and the authors found no significant group differences in changes in anxiety or depression scores.
For adults over 60 with memory concerns, the immediate implication is to bring those concerns to a qualified health professional. The study supports looking at the whole assessment rather than focusing only on a laboratory result.
Sleep, smoking, physical activity and blood pressure are reasonable topics for that discussion. Their presence in this cohort gives the service a set of health issues to review alongside reported cognitive changes. These are topics for individualized assessment rather than a personal treatment plan drawn from the study.
Questions that stay within the research's scope include:
These questions leave individual decisions with the clinical team. Readers seeking background can use this guide to how cognitive assessments and biomarkers fit together. For the sleep part of the conversation, reading about sleep apnoea and cognitive health provides related context.
Another practical point is how information is explained. In Monza, the conversation covered a person's risk profile and recommendations rather than simply delivering a test result. The authors argue that Brain Health Services could combine risk assessment with communication and risk reduction.
For a patient, that makes the discussion surrounding a result part of the assessment itself. The useful questions extend beyond whether a number is above a threshold. They also concern how the information fits with the person's reported changes and what the clinician recommends discussing next.
The news coverage of the study highlighted a link between subjective cognitive decline and dementia biomarkers. That connection should not be read as a prediction that everyone with memory concerns will develop dementia.
The Monza analysis captured people at one service at a point in time. It cannot establish that the reported health factors caused SCD or show who will develop dementia later. Its percentages describe the service cohort, not the general population.
Nor did the analysis test whether changing sleep or activity improved memory. The presence of a potentially modifiable factor is a reason for clinical discussion, not proof that it explains a person's symptoms.
The biomarker percentage also has a specific denominator: it applies to the participants with available p-Tau217 results. It should not be extended to everyone with SCD in the study. Keeping the tested subgroup separate from the full group prevents the headline figure from becoming a broader claim.
The authors identified another classification issue. Formal neuropsychological assessment was not performed systematically for everyone labelled as having SCD. Some participants may therefore have had subtle objective impairment that went undetected.
Several limits also affect the disclosure findings. The sample was modest and the follow-up was short. A positive response to a discussion is not evidence of lasting behaviour change or long-term psychological safety.
The discussion combined biomarker information with APOE genotype and individualized risk estimates. That design cannot separate the psychological effect of p-Tau217 information from the effects of the other information shared.
The authors say longer-term work is needed to assess psychological effects and sustained lifestyle changes. It is also needed to track progression to mild cognitive impairment or dementia. They report that a larger multicentre prospective observational cohort study led by the Brain Health Service network is ongoing.
Dementia prevention was not an outcome established by this analysis. Its contribution is to describe a service population and the early response to a structured risk discussion. Whether that approach changes longer-term outcomes remains a question for further research.
The most useful contribution is the way this study connects different parts of brain-health care: listening to memory concerns, reviewing relevant health factors and discussing test information in context. That is a broader task than sorting people by a blood result.
For long-term cognitive health, this is a useful direction for research and clinical services. Attention can shift from a single biomarker headline to the quality of assessment and the usefulness of communication. The next question is how well this model serves people over time.
People with memory concerns deserve both careful attention and explanations they can understand. The Monza study puts those needs within the same discussion. Its value lies in connecting the scientific questions with the experience of receiving care.
A blood-test headline raises a practical choice about seeking a broader assessment, and FitBrainLab takes on the work of explaining the evidence behind that choice. For readers unsettled by dementia coverage, its plain-language reporting puts early findings in perspective and supports informed thinking about memory and aging.
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.



Build habits that support memory, focus and a curious, connected life.
Read the Blog